Xenon Pharmaceuticals Inc. (XENE)
Company Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.
Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.
It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Country | Canada |
Founded | 1996 |
IPO Date | Nov 5, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 259 |
CEO | Ian C. Mortimer C.M.A., CPA, M.B.A. |
Contact Details
Address: 200 - 3650 Gilmore Way Burnaby, A1 V5G 48W British Columbia, Canada | |
Phone | (604) 484-3300 |
Website | xenon-pharma.com |
Stock Details
Ticker Symbol | XENE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001582313 |
CUSIP Number | 98420N105 |
ISIN Number | CA98420N1050 |
Employer ID | 98-0661854 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Ian C. Mortimer C.M.A., CPA, M.B.A. | President, Chief Executive Officer and Director |
Sherry Aulin | Chief Financial Officer |
Andrea DiFabio J.D. | Chief Legal Officer and Corporate Secretary |
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. | Chief Commercial Officer |
Dr. Christopher John Kenney M.D. | Chief Medical Officer |
Shelley McCloskey B.A. | Executive Vice President of Human Resources |
Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy and Innovation |
Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery |
Sheila M. Grant M.B.A., M.Sc., MBA | Executive Vice President of Research & Development Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 8, 2024 | 144 | Filing |
Mar 8, 2024 | 8-K | Current Report |
Mar 7, 2024 | 144 | Filing |
Mar 7, 2024 | 144 | Filing |
Feb 29, 2024 | 10-K | Annual Report |
Feb 29, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |